|
[1]
|
Fidler, I.J. and Ellis, L.M. (2000) Chemotherapeutic Drugs—More Really Is Not Better. Nature Medicine, 6, 500-502.
http://dx.doi.org/10.1038/74969
|
|
[2]
|
Hanahan, D., Bergers, G. and Bergsland, E. (2000) Less Is More, Regularly: Metronomic Dosing of Cytotoxic Drugs Can Target Tumor Angiogenesis in Mice. Journal of Clinical Investigation, 105, 1045-1047.
http://dx.doi.org/10.1172/JCI9872
|
|
[3]
|
Browder, T., Butterfield, C.E., Kraling, B.M., et al. (2000) Antiangiogenic Scheduling of Chemotherapy Improves Efficacy against Experimental Drug-Resistant Cancer. Cancer Research, 60, 1878-1886.
|
|
[4]
|
Klement, G., Baruchel, S., Rak, J., et al. (2000) Continuous Low-Dose Therapy with Vinblastine and VEGF Receptor-2 Antibody Induces Sustained Tumor Regression without Overt Toxicity. Journal of Clinical Investigation, 105, R15-R24.
http://dx.doi.org/10.1172/JCI8829
|
|
[5]
|
Huang, P., Chubb, S., Hertel, L.W., Grindey, G.B. and Plunkett, W. (1991) Action of 20,20-Difluorodeoxycytidine on DNA Synthesis. Cancer Research, 51, 6110-6117.
|
|
[6]
|
Heinemann, V., Xu, Y.-Z., Chubb, S., Sen, A., Hertel, L.W., Grindey, G.B., et al. (1992) Cellular Elimination of 20, 20-Difluorodeoxycytidine 50-Triphosphate: A Mechanism of Self-Potentiation. Cancer Research, 52, 533-539.
|
|
[7]
|
Heinemann, V., Xu, Y.-Z., Chubb, S., Sen, A., Hertel, L., G.B.G., et al. (1990) Inhibition of Ribonucleotide Reduction in CCRF-CEM Cells by 20,20-Difluorodeoxycytidine. Molecular Pharmacology, 38, 567-572.
|
|
[8]
|
Wang, J., Lohman, G.J.S. and Stubbe, J. (2007) Enhanced Subunit Interactions with Gemcitabine-50-Diphosphate Inhibit Ribonucleotide Reductases. Proceedings of the National Academy of Sciences of the United States of America, 104, 14324-14329.
http://dx.doi.org/10.1073/pnas.0706803104
|
|
[9]
|
Pratt, S.E., Durland-Busbice, S., Shepard, R.L., Heinz-Taney, K. and Dantzig, A.H. (2013) Human Carboxylesterase 2 Hydrolyzes the Prodrug of Gemcitabine (LY2334737) and Confers Prodrug Sensitivity to Cancer Cells. Clinical Cancer Research, 19, 1159-1168.
http://dx.doi.org/10.1158/1078-0432.CCR-12-1184
|
|
[10]
|
Sanghani, S., Sanghani, P., Schiel, M. and Bosron, W. (2009) Human Carboxylesterases: An Update on CES1, CES2 and CES3. Protein and Peptide Letters, 16, 1207-1214.
http://dx.doi.org/10.2174/092986609789071324
|
|
[11]
|
Pratt, S.E., Durland-Busbice, S., Shepard, R.L., Donoho, G.P., Starling, J.J., Wickremsinhe, E.R., Perkins, E.J. and Dantzig, A.H. (2013) Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts. Molecular Cancer Therapeutics, 4, 481-490.
http://dx.doi.org/10.1158/1535-7163.MCT-12-0654
|
|
[12]
|
Risau, W. (1997) Mechanisms of Angiogenesis. Nature, 386, 671-674.
http://dx.doi.org/10.1038/386671a0
|
|
[13]
|
Hanahan, D. and Folkman, J. (1996) Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis. Cell, 86, 353-64.
http://dx.doi.org/10.1016/S0092-8674(00)80108-7
|
|
[14]
|
Lawler, J. (2002) Thrombospondin-1 as an Endogenous Inhibitor of Angiogenesis and Tumor Growth. Journal of Cellular and Molecular Medicine, 6, 1-12.
http://dx.doi.org/10.1111/j.1582-4934.2002.tb00307.x
|
|
[15]
|
Salven, P., Manpaa, H., Orpana, A., Alitalo, K. and Joensuu, H. (1997) Serum Vascular Endothelial Growth Factor Is often Elevated in Disseminated Cancer. Clinical Cancer Research, 3, 647-51.
|
|
[16]
|
Mainetti, L.E., Rozados, V.R., Bonfil, R.D. and Scharovsky, O.G. (2005) Metronomic Therapy with Cyclophosphamide or Doxorubicin Inhibits Mouse Mammary Adenocarcinoma Growth and Metastasis Development. Proceedings of the American Association for Cancer Research, 46, 1337.
www.aacrmeetingabstracts.org/cgi/content/abstract/2005/1/1377-b
|
|
[17]
|
Mainetti, L.E., Rozados, V.R., Bonfil, R.D. and Scharovsky, O.G. (2006) Sinergistic Inhibitory Effect of Metronomic Therapy with Oral Cyclophosphamide Combined with a Cox-2 Inhibitor in a Mouse Mammary Adenocarcinoma. Proceedings of the American Association for Cancer Research, 47, 503.
|
|
[18]
|
Fersis, N., Smyczek-Gargya, B., Armeanu, S., et al. (2004) Changes in Vascular Endothelial Growth Factor (VEGF) after Chemoendocrine Therapy in Breast Cancer. European Journal of Gynaecological Oncology, 25, 45-50.
|
|
[19]
|
Wu, Y.L., Fu, S.L., Zhang, Y.P., Qiao, M.M. and Chen, Y. (2005) Cyclooxygenase-2 Inhibitors Suppress Angiogenesis and Growth of Gastric Cancer Xenografts. Biomedicine & Pharmacotherapy, 59, S289-S292.
http://dx.doi.org/10.1016/S0753-3322(05)80048-4
|
|
[20]
|
Colleoni, M., Orlando, L., Sanna, G., et al. (2006) Metronomic Low-Dose Oral Cyclophosphamide and Methotrexate Plus or Minus Thalidomide in Metastatic Breast Cancer: Antitumor Activity and Biological Effects. Annals of Oncology, 17, 232-238.
http://dx.doi.org/10.1093/annonc/mdj066
|
|
[21]
|
Correale, P., Cerretani, D., Remondo, C., et al. (2006) A Novel Metronomic Chemotherapy Regimen of Weekly Platinum and Daily Oral Etoposide in High-Risk Non-Small Cell Lung Cancer Patients. Oncology Reports, 16, 133-140.
http://dx.doi.org/10.3892/or.16.1.133
|
|
[22]
|
Rozados, V.R., Sanchez, A.M., Gervasoni, S.I., Berra, H.H., Matar, P. and Scharovsky, O.G. (2004) Metronomic Therapy with Cyclophosphamide Induces Rat Lymphoma and Sarcoma Regression, and Is Devoid of Toxicity. Annals of Oncology, 15, 1543-1550.
http://dx.doi.org/10.1093/annonc/mdh384
|
|
[23]
|
Klement, G., Baruchel, S., Rak, J., et al. (2000) Continuous Low-Dose Therapy with Vinblastine and VEGF Receptor-2 Antibody Induces Sustained Tumor Regression without Overt Toxicity. The Journal of Clinical Investigation, 105, R15-R24.
http://dx.doi.org/10.1172/JCI8829
|
|
[24]
|
Klement, G., Huang, P., Mayer, B., et al. (2002) Differences in Therapeutic Indexes of Combination Metronomic Chemotherapy and an Anti-VEGFR-2 Antibody in Multidrug-Resistant Human Breast Cancer Xenografts. Clinical Cancer Research, 8, 221-232.
|
|
[25]
|
Pietras, K. and Hanahan, D. (2005) A Multitargeted, Metronomic, and Maximum-Tolerated Dose “Chemo-Switch” Regimen Is Antiangiogenic, Producing Objective Responses and Survival Benefit in a Mouse Model of Cancer. Journal of Clinical Oncology, 23, 939-952.
http://dx.doi.org/10.1200/JCO.2005.07.093
|
|
[26]
|
Mancuso, P., Burlini, A., Pruneri, G., Goldhirsch, A., Martinelli, G. and Bertolini, F. (2001) Resting and Activated Endothelial Cells Are Increased in the Peripheral Blood of Cancer Patients. Blood, 97, 3658-3661.
http://dx.doi.org/10.1182/blood.V97.11.3658
|
|
[27]
|
Rabascio, C., Muratori, E., Mancuso, P., et al. (2004) Assessing Tumor Angiogenesis: Increased Circulating Ve-Cadherin RNA in Patients with Cancer Indicates Viability of Circulating Endothelial Cells. Cancer Research, 64, 4373-4377.
http://dx.doi.org/10.1158/0008-5472.CAN-04-0265
|
|
[28]
|
Dudek, A.Z. and Mahaseth, H. (2005) Circulating Angiogenic Cytokines in Patients with Advanced Non-Small Cell Lung Cancer: Correlation with Treatment Response and Survival. Cancer Investigation, 23, 193-200.
http://dx.doi.org/10.1081/CNV-200055949
|
|
[29]
|
Stempak, D., Gammon, J., Halton, J., Moghrabi, A., Koren, G. and Baruchel, S. (2006) A Pilot Pharmacokinetic and Antiangiogenic Biomarker Study of Celecoxib and Low-Dose Metronomic Vinblastine or Cyclophosphamide in Pediatric Recurrent Solid Tumors. Journal of Pediatric Hematology/Oncology, 28, 720-728.
http://dx.doi.org/10.1097/01.mph.0000243657.64056.c3
|
|
[30]
|
Monestiroli, S., Mancuso, P., Burlini, A., Pruneri, G., Dell’Agnola, C., Gobbi, A., Martinelli, G. and Bertonlini, F. (2001) Kinetics and Viability of Circulating Endothelial Cells as Surrogate Angiogenesis Marker in an Animal Model of Human Lymphoma. Cancer Research, 61, 4341-4344.
|
|
[31]
|
Capillo, M., Mancuso, P., Gobbi, A., Monestiroli, S., Pruneri, G., Dell’Agnola, C., Martinelli, G., Shultz, L. and Bertolini, F. (2003) Continuous Infusion of Endostatin Inhibits Differentiation, Mobilization and Clonogenic Potential of Endothelial Cell Progenitors. Clinical Cancer Research, 9, 377-382.
|
|
[32]
|
Kerbel, R.S. (1991) Inhibition of Tumor Angiogenesis as a Strategy to Circumvent Acquired Resistance to Anti-Cancer Therapeutic Agents. BioEssays, 13, 31-36.
http://dx.doi.org/10.1002/bies.950130106
|
|
[33]
|
Klement, G., Huang, P., Mayer, B., Green, S.K., Man, S., Bohlen, P., Hicklin, D. and Kerbel, R.S. (2002) Differences in Therapeutic Indexes of Combination Metronomic Chemotherapy and an Anti-VEGFR-2 Antibody in Multidrug-Resistant Human Breast Cancer Xenografts. Clinical Cancer Research, 8, 221-232.
|
|
[34]
|
Asahara, T., Takahashi, T., Masuda, H., Kalka, C., Chen, D., Iwaguro, H., Inai, Y., Silver, M. and Isner, J.M. (1999) VEGF Contributes to Postnatal Neovascularization by Mobilizing Bone Marrow-Derived Endothelial Progenitor Cells. The EMBO Journal, 18, 3964-3972.
http://dx.doi.org/10.1093/emboj/18.14.3964
|
|
[35]
|
Twardowski, P.W., Smith-Powell, L., Carroll, M., VanBalgooy, J., Ruel, C., Frankel, P. and Synold, T.W. (2008) Biologic Markers of Angiogenesis: Circulating Endothelial Cells in Patients with Advanced Malignancies Treated on Phase I Protocol with Metronomic Chemotherapy and Celecoxib. Cancer Investigation, 26, 53-59.
http://dx.doi.org/10.1080/07357900701681541
|
|
[36]
|
Bocci, G., Nicolaou, K.C. and Kerbel, R.S. (2002) Protracted Low-Dose Effects on Human Endothelial Cell Proliferation and Survival in Vitro Reveal a Selective Antiangiogenic Window for Various Chemotherapeutic Drugs. Cancer Research, 62, 6938-6943.
|
|
[37]
|
Shaked, Y., Bertolini, F., Man, S., Rogers, M.S., Cervi, D., Foutz, T., Rawn, K., Voskas, D., Dumont, D.J., Ben-David, Y., Layler, J., Henkin, J., Huber, J., Hicklin, D.J., D’Amato, R.J. and Kerbel, R.S. (2005) Genetic Heterogeneity of the Vasculogenic Phenotype Parallels Angiogenesis; Implications for Cellular Surrogate Marker Analysis of Antiangiogenesis. Cancer Cell, 7, 101-111.
|
|
[38]
|
Shaked, Y., Emmenegger, U., Man, S., Cervi, D., Bertolini, F., Ben-David, Y. and Kerbel, R.S. (2005) The Optimal Biological Dose of Metronomic Chemotherapy Regimens Is Associated with Maximum Antiangiogenic Activity. Blood, 106, 3058-3061.
http://dx.doi.org/10.1182/blood-2005-04-1422
|
|
[39]
|
Jimenez, B., Volpert, O.V., Crawford, S.E., Febbraio, M., Silverstein, R.L. and Bouck, N. (2000) Signals Leading to Apoptosis-Dependent Inhibition of Neovascularization by Thrombospondin-1. Nature Medicine, 6, 41-48.
http://dx.doi.org/10.1038/71517
|
|
[40]
|
Rozados, V.R., Mainetti, L.E., Rico, M.J., Zacarías Fluck, M.F., Matar, P. and Scharovsky, O.G. (2007) Antiangiogenic and Inmunomodulatory Effect of the Metronomic Therapy with Cyclophosphamide [Abstract]. Biocell, 3, 119.
|
|
[41]
|
Bolhuis, H., Van Veen, H.W., Poolman, B., Driessen, A.J. and Konings, W.N. (1997) Mechanisms of Multidrug Transporters. FEMS Microbiology Reviews, 21, 55-84.
http://dx.doi.org/10.1111/j.1574-6976.1997.tb00345.x
|
|
[42]
|
Kawase, M. and Motohashi, N. (2003) New Multidrug Resistance Reversal Agents. Current Drug Targets, 4, 31-43.
http://dx.doi.org/10.2174/1389450033347064
|
|
[43]
|
Szakacs, G., Paterson, J.K., Ludwig, J.A., Booth-Genthe, C. and Gottesman, M.M. (2006) Targeting Multidrug Resistance in Cancer. Nature Reviews Drug Discovery, 5, 219-234.
http://dx.doi.org/10.1038/nrd1984
|
|
[44]
|
Ozben, T. (2006) Mechanisms and Strategies to Overcome Multiple Drug Resistance in Cancer. FEBS Letters, 580, 2903-2909.
http://dx.doi.org/10.1016/j.febslet.2006.02.020
|
|
[45]
|
Dubikovskaya, E.A., Thorne, S.H., Pillow, T.H., Contag, C.H. and Wender, P.A. (2008) Overcoming Multidrug Resistance of Small-Molecule Therapeutics through Conjugation with Releasable Octaarginine Transporters. Proceedings of the National Academy of Sciences of the United States of America, 105, 12128-12133.
http://dx.doi.org/10.1073/pnas.0805374105
|
|
[46]
|
Baguley, B.C. (2010) Multidrug Resistance in Cancer. Methods in Molecular Biology, 596, 1-14.
http://dx.doi.org/10.1007/978-1-60761-416-6_1
|
|
[47]
|
Ling, V. (1997) Multidrug Resistance: Molecular Mechanisms and Clinical Relevance. Cancer Chemotherapy and Pharmacology, 40, S3-S8.
http://dx.doi.org/10.1007/s002800051053
|
|
[48]
|
Gillet, J.P., Efferth, T. and Remacle, J. (2007) Chemotherapy-Induced Resistance by ATP-Binding Cassette Transporter Genes. Biochimica et Biophysica Acta, 1775, 237-262.
|
|
[49]
|
Ejendal, K.F. and Hrycyna, C.A. (2002) Multidrug Resistance and Cancer: The Role of the Human ABC Transporter ABCG2. Current Protein & Peptide Science, 3, 503-511.
http://dx.doi.org/10.2174/1389203023380521
|
|
[50]
|
Sarkadi, B., Ozvegy-Laczka, C., Nemet, K. and Varadi, A. (2004) ABCG2—A Transporter for All Seasons. FEBS Letters, 567, 116-120.
http://dx.doi.org/10.1016/j.febslet.2004.03.123
|
|
[51]
|
Loebinger, M.R., Giangreco, A., Groot, K.R., Prichard, L., Allen, K., Simpson, C., Bazley, L., Navani, N., Tibrewal, S., Davies, D. and Janes, S.M. (2008) Squamous Cell Cancers Contain a Side Population of Stem-Like Cells That Are Made Chemosensitive by ABC Transporter Blockade. British Journal of Cancer, 98, 380-387.
http://dx.doi.org/10.1038/sj.bjc.6604185
|
|
[52]
|
Hadnagy, A., Gaboury, L., Beaulieu, R. and Balicki, D. (2006) SP Analysis May Be Used to Identify Cancer Stem Cell Populations. Experimental Cell Research, 312, 3701-3710.
http://dx.doi.org/10.1016/j.yexcr.2006.08.030
|
|
[53]
|
Keshet, G.I., Goldstein, I., Itzhaki, O., Cesarkas, K., Shenhav, L., Yakirevitch, A., Treves, A.J., Schacter, J., Amariglio, N. and Rechavi, G. (2008) MDR1 Expression Identifies Human Melanoma Stem Cells. Biochemical and Biophysical Research Communications, 368, 930-936.
http://dx.doi.org/10.1016/j.bbrc.2008.02.022
|
|
[54]
|
Roninson, I.B., Abelson, H.T., Housman, D.E., Howell, N. and Varshavsky, A. (1984) Amplification of Specific DNA Sequences Correlates with Multi-Drug Resistance in Chinese Hamster Cells. Nature, 309, 626-628.
http://dx.doi.org/10.1038/309626a0
|
|
[55]
|
Roninson, I.B. (1983) Detection and Mapping of Homologous, Repeated and Amplified DNA Sequences by DNA renaturation in Agarose Gels. Nucleic Acids Research, 11, 5413-5431.
|
|
[56]
|
Gros, P., Croop, J., Roninson, I., Varshavsky, A. and Housman, D.E. (1986) Isolation and Characterization of DNA Sequences Amplified in Multidrug-Resistant Hamster Cells. Proceedings of the National Academy of Sciences of the United States of America, 83, 337-341.
http://dx.doi.org/10.1073/pnas.83.2.337
|
|
[57]
|
Comerford, K.M., Wallace, T.J., Karhausen, J., Louis, N.A., Montalto, M.C. and Colgan, S.P. (2002) Hypoxia-Inducible Factor-1-Dependent Regulation of the Multidrug Resistance (MDR1) Gene. Cancer Research, 62, 3387-3394.
|
|
[58]
|
Liu, L., Ning, X., Sun, L., Zhang, H., Shi, Y., Guo, C., Han, S., Liu, J., Sun, S., Han, Z., Wu, K. and Fan, D. (2008) Hypoxiainducible Factor-1 Alpha Contributes to Hypoxia-Induced Chemoresistance in Gastriccancer. Cancer Science, 99, 121-128.
|
|
[59]
|
Han, H.K., Han, C.Y., Cheon, E.P., Lee, J. and Kang, K.W. (2007) Role of Hypoxia-Inducible Factoralpha in Hepatitis-B-Virus X Protein-Mediated MDR1 Activation. Biochemical and Biophysical Research Communications, 357, 567-573.
http://dx.doi.org/10.1016/j.bbrc.2007.04.012
|
|
[60]
|
Song, X., Liu, X., Chi, W., Liu, Y., Wei, L., Wang, X. and Yu, J. (2006) Hypoxiainduced Resistance to Cisplatin and Doxorubicin in Non-Small Cell Lung Cancer Is Inhibited by Silencing of HIF-1 Alpha Gene. Cancer Chemotherapy and Pharmacology, 58, 776-784.
http://dx.doi.org/10.1007/s00280-006-0224-7
|
|
[61]
|
Krishnamurthy, P., Ross, D.D., Nakanishi, T., Bailey-Dell, K., Zhou, S., Mercer, K.E., Sarkadi, B., Sorrentino, B.P. and Schuetz, J.D. (2004) The Stem Cell Marker Bcrp/ABCG2 Enhances Hypoxic Cell Survival through Interactions with Heme. The Journal of Biological Chemistry, 279, 24218-24225.
http://dx.doi.org/10.1074/jbc.M313599200
|
|
[62]
|
Kohno, K., Sato, S., Takano, H., Matsuo, K. and Kuwano, M. (1989) The Direct Activation of Human Multidrug Resistance Gene (MDR1) by Anticancer Agents. Biochemical and Biophysical Research Communications, 165, 1415-1421.
http://dx.doi.org/10.1016/0006-291X(89)92761-7
|
|
[63]
|
Chaudhary, P.M. and Roninson, I.B. (1993) Induction of Multidrug Resistance in Human Cells by Transient Exposure to Different Chemotherapeutic Drugs. Journal of the National Cancer Institute, 85, 632-639.
http://dx.doi.org/10.1093/jnci/85.8.632
|
|
[64]
|
Danial, N.N. (2007) BCL-2 Family Proteins: Critical Checkpoints of Apoptotic Cell Death. Clinical Cancer Research, 13, 7254-7263.
http://dx.doi.org/10.1158/1078-0432.CCR-07-1598
|
|
[65]
|
Forte, M. and Bernardi, P. (2006) The Permeability Transition and BCL-2 Family Proteins in Apoptosis: Co-Conspirators or Independent Agents? Cell Death and Differentiation, 13, 1287-1290.
http://dx.doi.org/10.1038/sj.cdd.4401957
|
|
[66]
|
Kramer, A., Lukas, J. and Bartek, J. (2004) Checking Out the Centrosome. Cell Cycle, 3, 1390-1393.
http://dx.doi.org/10.4161/cc.3.11.1252
|
|
[67]
|
McDermott, K.M., Zhang, J., Holst, C.R., Kozakiewicz, B.K., Singla, V. and Tlsty, T.D. (2006) p16INK4a Prevents Centrosome Dysfunction and Genomic Instability in Primary Cells. PLoS Biology, 4, e51.
http://dx.doi.org/10.1371/journal.pbio.0040051
|
|
[68]
|
Loeb, L.A., Bielas, J.H. and Beckman, R.A. (2008) Cancers Exhibit a Mutator Phenotype: Clinical Implications. Cancer Research, 68, 3551-3557.
http://dx.doi.org/10.1158/0008-5472.CAN-07-5835
|
|
[69]
|
Bodey, G.P., Buckley, M., Sathe, Y.S. and Freireich, E.J. (1966) Quantitative Relationships between Circulating Leukocytes and Infection in Patients with Acute Leukemia. Annals of Internal Medicine, 64, 328-340.
http://dx.doi.org/10.7326/0003-4819-64-2-328
|
|
[70]
|
Blackwell, S. and Crawford, J. (1994) Filgrastim (r-metHuG-CSF) in the Chemotherapy Setting. In: Morstyn, G., Dexter, T.M. and Foote, M., Eds., Filgrastim (r-metHuG-CSF) in Clinical Practice, Marcel Dekker, New York, 103-106.
|
|
[71]
|
Su, Y.B., Sohn, S., Krown, S.E., et al. (2004) Selective CD4+ Lymphopenia in Melanoma Patients Treated with Temozolomide: A Toxicity with Therapeutic Implications. Journal of Clinical Oncology, 22, 610-616.
http://dx.doi.org/10.1200/JCO.2004.07.060
|
|
[72]
|
Amato, R. and Stepankiw, M. (2013) Evaluation of Everolimus in Renal Cell Cancer. Drug Evaluations, 14, 1229-1240.
http://dx.doi.org/10.1517/14656566.2013.791677
|
|
[73]
|
Layman, R.M., Ruppert, A.S., Lynn, M., Mrozek, E., Ramaswamy, B., Lustberg, M., Wesolowski, R., Ottman, S., Carthers, S., Bingman, A., Reinbolt, R., Kraut, E.H. and Shapiro, C.L. (2013) Severe and Prolonged Lymphopenia Observed in Patients Treated with Bendamustine and Erlotinib for Metastatic Triple Negative Breast Cancer. Cancer Chemotherapy and Pharmacology, 71, 1183-1190.
http://dx.doi.org/10.1007/s00280-013-2112-2
|
|
[74]
|
Dighiero, G. (1996) Adverse and Beneficial Immunological Effects of Purine Nucleoside Analogs. Hematology and Cell Therapy, 38, S75-S81
|
|
[75]
|
Ray-Coquard, I., Borg, C., Bachelot, T., Sebban, C., Phillip, I., Clapisson, G., Le Cesne, A., Biron, P., Chauvin, F. and Blay, J.Y. (2003) Baseline and Early Lymphopenia Predict for the Risk of Febrile Neutropenia after Chemotherapy. British Journal of Cancer, 88, 181-186.
http://dx.doi.org/10.1038/sj.bjc.6600724
|
|
[76]
|
Ghiringhelli, F., Menard, C., Puig, P.E., et al. (2007) Metronomic Cyclophosphamide Regimen Selectively Depletes CD4+CD25+ Regulatory T Cells and Restores T and NK Effector Functions in End Stage Cancer Patients. Cancer Immunology, Immunotherapy, 56, 641-648.
http://dx.doi.org/10.1007/s00262-006-0225-8
|
|
[77]
|
Tannock, I.F., Ahles, T.A., Ganz, P.A. and van Dam, F.S. (2004) Cognitive Impairment Associated with Chemotherapy for Cancer: Report of a Workshop. Journal of Clinical Oncology, 22, 2233-2239.
http://dx.doi.org/10.1200/JCO.2004.08.094
|
|
[78]
|
Ahles, T.A. and Saykin, A.J. (2002) Breast Cancer Chemotherapy-Related Cognitive Dysfunction. Clinical Breast Cancer, 3, S84-S90.
http://dx.doi.org/10.3816/CBC.2002.s.018
|
|
[79]
|
Ferguson, R.J. and Ahles, T.A. (2003) Low Neuropsychologic Performance among Adult Cancer Survivors Treated with Chemotherapy. Current Neurology and Neuroscience Reports, 3, 215-222.
http://dx.doi.org/10.1007/s11910-003-0081-2
|
|
[80]
|
Anderson-Hanley, C., Sherman, M.L., Riggs, R., Agocha, V.V. and Compas, B.E. (2003) Neuropsychological Effects of Treatments for Adults with Cancer: A Meta-Analysis and Review of the Literature. Journal of the International Neuropsychological Society, 9, 967-982.
http://dx.doi.org/10.1017/s1355617703970019
|
|
[81]
|
Saykin, A.J., Ahles, T.A. and McDonald, B.C. (2003) Mechanisms of Chemotherapy-Induced Cognitive Disorders: Neuropsychological, Pathophysiological and Neuroimaging Perspectives. Seminars in Clinical Neuropsychiatry, 8, 201-216.
|
|
[82]
|
Stemmer, S., Stears, J.C., Burton, B.S., et al. (1994) White Matter Changes in Patients with Breast Cancer Treated with High-Dose Chemotherapy and Autologous Bone Marrow Support. American Journal of Neuroradiology, 15, 1267-1273.
|
|
[83]
|
Wefel, J.S., Lenzi, R., Theriault, R., et al. (2004) “Chemobrain” in Breast Carcinoma? A Prologue. Cancer, 101, 466-475.
http://dx.doi.org/10.1002/cncr.20393
|
|
[84]
|
Meyers, C.A., Albitar, M. and Estey, E. (2005) Cognitive Impairment, Fatigue, and Cytokine Levels in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome. Cancer, 104, 788-793.
http://dx.doi.org/10.1002/cncr.21234
|
|
[85]
|
Ahles, T.A., Silberfarb, P.M., Maurer, L.H., et al. (1998) Psychological and Neuropsychological Functioning of Patients with Limited Smallcell Lung Cancer Treated with Chemotherapy and Radiation Therapy with or without Warfarin, a Study for Cancer and Leukemia Group B. Journal of Clinical Oncology, 16, 1954-1960.
|
|
[86]
|
Wagner, L.I., Sweet, J.J., Butt, Z., et al. (2006) Trajectory of Cognitive Impairment during Breast Cancer Treatment: A Prospective Analysis. Journal of Clinical Oncology, 24, 8500.
|
|
[87]
|
Heflin, L.H., Meyerowitz, B.E., Hall, P., et al. (2005) Cancer as a Risk Factor for Long-Term Cognitive Deficits and Dementia. Journal of the National Cancer Institute, 97, 854-856.
http://dx.doi.org/10.1093/jnci/dji137
|
|
[88]
|
Smith, A.J., Oertle, J. and Prato, D. (2015) Genetically Targeted Fractionated Chemotherapy. Journal of Cancer Therapy, 6, 182-198.
http://dx.doi.org/10.4236/jct.2015.62021
|
|
[89]
|
Kafka, M.S. (1974) The Effect of Insulin on the Permeability of Phosphatidyl Choline Bimolecular Membranes to Glucose. The Journal of Membrane Biology, 18, 81-94.
http://dx.doi.org/10.1007/BF01870104
|
|
[90]
|
Lee, C., Raffaghello, L., Brandhorst, S., Safdie, F.M., Bianchi, G., Martin-Montalvo, A., Pistoia, V., Wei, M., Hwang, S., Merlino, A., Emionite, L., Cabo, R. and Longo, V. (2012) Fasting Cycles Retard Growth of Tumor and Sensitize a Range of Cancer Cell Types to Chemotherapy. Science Translational Medicine, 4, 124ra27.
|